{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-085188","form_type":"8-K","ticker":"RIGL","cik":"0001034842","company_name":"RIGEL PHARMACEUTICALS INC","filed_at":"2022-08-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:54.702664+00:00","generated_at":"2026-06-24T05:39:04.016433+00:00","sec_items":["1.01","2.02","2.03","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Rigel Q2 TAVALISSE net product sales $18.6M; licenses olutasidenib from Forma; draws $10M term loan","bullets":["TAVALISSE net product sales of $18.6M, up 9% YoY; total revenues $29.8M; net loss $13.5M ($0.08/share).","Exclusive license from Forma for olutasidenib (mIDH1 inhibitor) for R/R AML; $2M upfront, up to $233M milestones; PDUFA Feb 15, 2023.","Amended MidCap credit agreement: extended maturity to Sept 2026, interest-only to Oct 2024; drew $10M fourth tranche term loan.","Completed enrollment (280 patients) in Phase 3 COVID-19 trial of fostamatinib; top-line data expected Q4 2022.","Knight license for TAVALISSE in Latin America: $2M upfront, up to $20M milestones; Kissei NDA submitted in Japan for ITP."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-085188","json":"https://secwatch.observer/filing/0001104659-22-085188.json","markdown":"https://secwatch.observer/filing/0001104659-22-085188.md","text":"https://secwatch.observer/filing/0001104659-22-085188.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1034842/000110465922085188/0001104659-22-085188-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1034842/000110465922085188/tm2222339d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T05:39:04.016433+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}